NCT06779318View on ClinicalTrials.gov

Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

464

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2028

Conditions

Pancreatic CancerPostoperative Adjuvant TherapyMaintenance Therapy

Interventions

DRUG

S-1

Tegafur, Gimeracil, and Oteracil Potassium (S-1) 40-60 mg per dose, orally (p.o.), twice daily (BID), from Day 1 to Day 28, with a 6-week cycle, for a total of 8 cycles; or from Day 1 to Day 14, with a 3-week cycle, for a total of 16 cycles.

Trial Locations (1)

025

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER